

Bcl-6 (C-19): sc-368

BACKGROUND

Bcl-6, a transcriptional repressor, binds Stat recognition-like DNA elements and influences germinal center development and Th1/Th2 differentiation. Bcl-6 negatively regulates NF κ B expression, thereby inhibiting NF κ B-mediated cellular functions. HDAC- and silent information regulator (SIR)-2-dependent acetylation of Bcl-6 causes downregulation of activity by inhibiting the ability of Bcl-6 to recruit complexes containing histone deacetylases (HDAC). Bcl-6 is frequently deregulated in non-Hodgkin's B cell lymphomas. The human Bcl6 gene has been shown to encode a protein of 706 amino acids.

CHROMOSOMAL LOCATION

Genetic locus: BCL6 (human) mapping to 3q27.3; Bcl6 (mouse) mapping to 16 B1.

SOURCE

Bcl-6 (C-19) is an affinity purified rabbit polyclonal antibody raised against a peptide mapping at the C-terminus of Bcl-6 of human origin.

PRODUCT

Each vial contains 200 μ g IgG in 1.0 ml of PBS with < 0.1% sodium azide and 0.1% gelatin.

Blocking peptide available for competition studies, sc-368 P, (100 μ g peptide in 0.5 ml PBS containing < 0.1% sodium azide and 0.2% BSA).

Available as TransCruz reagent for Gel Supershift and ChIP applications, sc-368 X, 200 μ g/0.1 ml.

APPLICATIONS

Bcl-6 (C-19) is recommended for detection of Bcl-6 of mouse, rat and human origin by Western Blotting (starting dilution 1:200, dilution range 1:100-1:1000), immunoprecipitation [1-2 μ g per 100-500 μ g of total protein (1 ml of cell lysate)], immunofluorescence (starting dilution 1:50, dilution range 1:50-1:500) and solid phase ELISA (starting dilution 1:30, dilution range 1:30-1:3000).

Bcl-6 (C-19) is also recommended for detection of Bcl-6 in additional species, including equine, canine, bovine and porcine.

Suitable for use as control antibody for Bcl-6 siRNA (h): sc-29791, Bcl-6 siRNA (m): sc-29792, Bcl-6 shRNA Plasmid (h): sc-29791-SH, Bcl-6 shRNA Plasmid (m): sc-29792-SH, Bcl-6 shRNA (h) Lentiviral Particles: sc-29791-V and Bcl-6 shRNA (m) Lentiviral Particles: sc-29792-V.

Bcl-6 (C-19) X TransCruz antibody is recommended for Gel Supershift and ChIP applications.

Molecular Weight of Bcl-6: 95 kDa.

Positive Controls: Bcl-6 (h2): 293T Lysate: sc-112850, BJAB whole cell lysate: sc-2207 or Ramos cell lysate: sc-2216.


STORAGE

Store at 4° C, **DO NOT FREEZE**. Stable for one year from the date of shipment. Non-hazardous. No MSDS required.


RESEARCH USE

For research use only, not for use in diagnostic procedures.

DATA



Bcl-6 (C-19): sc-368. Western blot analysis of Bcl-6 expression in non-transfected: sc-117752 (A) and human Bcl-6 transfected: sc-112850 (B) 293T whole cell lysates.



Bcl-6 (C-19): sc-368. Immunofluorescence staining of methanol-fixed Hep G2 cells showing nuclear and cytoplasmic localization.

SELECT PRODUCT CITATIONS

1. Albagli-Curiel, O., et al. 1998. Increased expression of the LAZ3 (BCL6) proto-oncogene accompanies murine skeletal myogenesis. *Differentiation* 64: 33-44.
2. Qin, X.F., et al. 1998. OCA-B integrates B cell antigen receptor-, CD40L- and IL 4-mediated signals for the germinal center pathway of B cell development. *EMBO J.* 17: 5066-5075.
3. Scheeren, F.A., et al. 2008. IL-21 is expressed in Hodgkin lymphoma and activates STAT5: evidence that activated STAT5 is required for Hodgkin lymphomagenesis. *Blood* 111: 4706-4715.
4. Schmidlin, H., et al. 2008. Spi-B inhibits human plasma cell differentiation by repressing BLIMP1 and XBP-1 expression. *Blood* 112: 1804-1812.
5. Diehl, S.A., et al. 2008. STAT3-mediated up-regulation of BLIMP1 is coordinated with Bcl6 down-regulation to control human plasma cell differentiation. *J. Immunol.* 180: 4805-4815.
6. Chen, Y., et al. 2009. Computational and functional analysis of growth hormone (GH)-regulated genes identifies the transcriptional repressor B-cell lymphoma 6 (Bcl6) as a participant in GH-regulated transcription. *Endocrinology* 150: 3645-3654.
7. Meyer, R.D., et al. 2009. Male-specific hepatic Bcl6: growth hormone-induced block of transcription elongation in females and binding to target genes inversely coordinated with STAT5. *Mol. Endocrinol.* 23: 1914-1926.
8. Jin, H.Y., et al. 2013. MicroRNA-17-92 plays a causative role in lymphomagenesis by coordinating multiple oncogenic pathways. *EMBO J.* 32: 2377-2391.



Try **Bcl-6 (D-8): sc-7388** or **Bcl-6 (H-12): sc-365618**, our highly recommended monoclonal alternatives to Bcl-6 (C-19). Also, for AC, HRP, FITC, PE, Alexa Fluor[®] 488 and Alexa Fluor[®] 647 conjugates, see **Bcl-6 (D-8): sc-7388**.